BACKGROUND: Although recent data support an early invasive management in acute coronary syndromes (ACS), overall evidence appears conflicting. We performed a metaregression to explore the impact of intracoronary stenting and aggressive antiplatelet treatment on the risk/benefit ratio of an early invasive approach. METHODS: We searched several databases up to March 2004 for randomized trials comparing an early invasive versus delayed invasive or conservative management in ACS. Random-effects odds ratios were computed for death and/or myocardial infarction at the longest follow-up. Log (odds ratios) were tested for interaction with stenting and aggressive antiplatelet treatment (ie, glycoprotein IIb/IIIa inhibitors or thienopyridines in addition to aspirin). RESULTS: Ten trials (9990 patients, median follow-up 12 months) were pooled. Overall, an early invasive management was associated with significantly reduced rates of death or myocardial infarction (P = .01). Metaregression analysis showed that the 2 most significant predictors of the benefits of an early invasive strategy in patients with ACS on event-free survival were the use, in subjects managed invasively, of aggressive antiplatelet treatment (P = .005) and stenting (P = .011). Moreover, both stenting and aggressive antiplatelet treatment were significantly associated with reduced mortality (respectively, P = .014 and P = .009) and correlated to each other (r = 0.76, P = .010). CONCLUSIONS: This study shows that the benefits of an early invasive approach in patients with ACS are significantly associated with concomitant aggressive antiplatelet treatment and stenting. These findings thus suggest the overall superiority of an early invasive approach in ACS, as long as state-of-the-art therapies are implemented.
BACKGROUND: Although recent data support an early invasive management in acute coronary syndromes (ACS), overall evidence appears conflicting. We performed a metaregression to explore the impact of intracoronary stenting and aggressive antiplatelet treatment on the risk/benefit ratio of an early invasive approach. METHODS: We searched several databases up to March 2004 for randomized trials comparing an early invasive versus delayed invasive or conservative management in ACS. Random-effects odds ratios were computed for death and/or myocardial infarction at the longest follow-up. Log (odds ratios) were tested for interaction with stenting and aggressive antiplatelet treatment (ie, glycoprotein IIb/IIIa inhibitors or thienopyridines in addition to aspirin). RESULTS: Ten trials (9990 patients, median follow-up 12 months) were pooled. Overall, an early invasive management was associated with significantly reduced rates of death or myocardial infarction (P = .01). Metaregression analysis showed that the 2 most significant predictors of the benefits of an early invasive strategy in patients with ACS on event-free survival were the use, in subjects managed invasively, of aggressive antiplatelet treatment (P = .005) and stenting (P = .011). Moreover, both stenting and aggressive antiplatelet treatment were significantly associated with reduced mortality (respectively, P = .014 and P = .009) and correlated to each other (r = 0.76, P = .010). CONCLUSIONS: This study shows that the benefits of an early invasive approach in patients with ACS are significantly associated with concomitant aggressive antiplatelet treatment and stenting. These findings thus suggest the overall superiority of an early invasive approach in ACS, as long as state-of-the-art therapies are implemented.
Authors: P R Stella; G Pavlakis; P Agostoni; H M Nathoe; S Hoseyni Guyomi; B J Hamer; T X Wildbergh; P A Doevendans; E Van Belle Journal: Neth Heart J Date: 2010-10 Impact factor: 2.380
Authors: David H Fitchett; Bjug Borgundvaag; Warren Cantor; Eric Cohen; Sanjay Dhingra; Stephen Fremes; Milan Gupta; Michael Heffernan; Heather Kertland; Mansoor Husain; Anatoly Langer; Eric Letovsky; Shaun G Goodman Journal: Can J Cardiol Date: 2006-06 Impact factor: 5.223
Authors: Giuseppe G L Biondi-Zoccai; Marzia Lotrionte; Antonio Abbate; Luca Testa; Enrico Remigi; Francesco Burzotta; Marco Valgimigli; Enrico Romagnoli; Filippo Crea; Pierfrancesco Agostoni Journal: BMJ Date: 2006-01-16
Authors: Elena Franchi; Paolo Marino; Giuseppe G Biondi-Zoccai; Giuseppe De Luca; Corrado Vassanelli; Pierfrancesco Agostoni Journal: Curr Cardiol Rep Date: 2009-09 Impact factor: 2.931
Authors: Thomas A Kite; Peter F Ludman; Chris P Gale; Jianhua Wu; Adriano Caixeta; Jacques Mansourati; Manel Sabate; Pilar Jimenez-Quevedo; Luciano Candilio; Parham Sadeghipour; Angel M Iniesta; Stephen P Hoole; Nick Palmer; Albert Ariza-Solé; Alim Namitokov; Hector H Escutia-Cuevas; Flavien Vincent; Otilia Tica; Mzee Ngunga; Imad Meray; Andrew Morrow; Md Minhaj Arefin; Steven Lindsay; Ghada Kazamel; Vinoda Sharma; Aly Saad; Gianfranco Sinagra; Federico Ariel Sanchez; Marek Roik; Stefano Savonitto; Marija Vavlukis; Shankar Sangaraju; Iqbal S Malik; Sharon Kean; Nick Curzen; Colin Berry; Gregg W Stone; Bernard J Gersh; Anthony H Gershlick Journal: J Am Coll Cardiol Date: 2021-05-25 Impact factor: 24.094
Authors: Arturo Giordano; Michele Polimeno; Nicola Corcione; Luciano Fattore; Luigi Di Lorenzo; Giuseppe Biondi-Zoccai; Paolo Ferraro; Maria Fiammetta Romano Journal: Curr Cardiol Rev Date: 2012-02